Celldex Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $3,191 | $2,498 | $156 | $4,131 |
Gross Profit | 3,191 | 1,701 | -619 | 3,372 |
EBITDA | -42,121 | -45,520 | -39,833 | -34,368 |
EBIT | -46,317 | -40,608 | -35,127 | |
Net Income | -42,121 | -35,842 | -32,808 | -43,306 |
Net Change In Cash | 3,191 | 2,498 | 156 | 4,131 |
Free Cash Flow | -54,719 | -29,601 | -40,982 | -33,199 |
Cash | 36,399 | 42,739 | 115,077 | 34,814 |
Basic Shares | 66,294 | 66,019 | 58,871 | 52,028 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $6,883 | $2,357 | $4,651 | $7,418 |
Gross Profit | 3,875 | 957 | 1,583 | -35,116 |
EBITDA | -139,034 | -101,867 | -67,558 | -38,197 |
EBIT | -142,042 | -103,267 | -70,626 | -40,197 |
Net Income | -141,429 | -122,783 | -70,511 | -59,780 |
Net Change In Cash | 6,883 | 2,357 | 4,651 | 7,418 |
Cost of Revenue | -4,693 | 32,604 | ||
Free Cash Flow | -109,109 | -105,560 | -62,158 | -41,956 |
Cash | 34,814 | 29,429 | 39,143 | 43,836 |
Basic Shares | 48,449 | 46,888 | 42,870 | 29,640 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.64 |
2024-06-30 | -$0.54 |
2024-03-31 | -$0.56 |
2023-12-31 | -$0.83 |
